Candriam Luxembourg S.C.A.acquired a new position in shares of HUTCHISON CHINA/S (NASDAQ:HCM) during the 2nd quarter, according to its most recent 13F filing with the SEC.The firm acquired 35,000 shares of the company’s stock, valued at approximately $965,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business.Schroder Investment Management Group increased its holdings in shares of HUTCHISON CHINA/S by 47.6% in the 1st quarter.Schroder Investment Management Group now owns 3,983,910 shares of the company’s stock valued at $72,826,000 after acquiring an additional 1,285,243 Capital International Investors increased its holdings in shares of HUTCHISON CHINA/S by 58.7% in the 1st quarter.Capital International Investors now owns 3,045,080 shares of the company’s stock valued at $54,355,000 after acquiring an additional 1,126,259 Sands Capital Management LLC increased its holdings in shares of HUTCHISON CHINA/S by 57.4% in the 1st quarter.Sands Capital Management LLC now owns 2,371,925 shares of the company’s stock valued at $42,339,000 after acquiring an additional 865,350 JPMorgan Chase & Co.
increased its holdings in shares of HUTCHISON CHINA/S by 31.1% in the 1st quarter.JPMorgan Chase & Co.now owns 1,147,267 shares of the company’s stock valued at $20,479,000 after acquiring an additional 272,162 Finally, Goldman Sachs Group Inc.increased its holdings in shares of HUTCHISON CHINA/S by 45.7% in the 4th quarter.Goldman Sachs Group Inc.
now owns 280,851 shares of the company’s stock valued at $7,041,000 after acquiring an additional 88,153 Institutional investors own 30.90% of the company’s stock.
Get HUTCHISON CHINA/S alerts: HUTCHISON CHINA/S stock opened at $26.99 on Friday.The company has a debt-to-equity ratio of 0.10, a current ratio of 2.80 and a quick ratio of 2.66.HUTCHISON CHINA/S has a 1-year low of $14.74 and a 1-year high of $29.92.The business has a fifty day moving average price of $26.16 and a 200-day moving average price of $23.48.
A number of brokerages have recently issued reports on HCM.
Zacks Investment Research upgraded HUTCHISON CHINA/S from a “sell” rating to a “hold” rating in a report on Thursday, July 9th.BidaskClub downgraded HUTCHISON CHINA/S from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th.
Finally, ValuEngine downgraded HUTCHISON CHINA/S from a “buy” rating to a “hold” rating in a report on Thursday, July 2nd.Two equities research analysts have hold rating and five have assigned a buy rating to the company.
The stock presently has an average rating of “Buy” and a consensus target price of $26.50.
HUTCHISON CHINA/S Profile
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People’s Republic of China and Hong Kong.
The company operates through Innovation Platform and Commercial Platform segments.
Featured Story: Recession.